We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Evaluates teclistamab's efficacy in relapsed/refractory Waldenstrom macroglobulinemia, implying a potential new treatment option.
No takes yet. Share an insight, caveat, or question.
Kaščák et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: